Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative study
Background: Coronavirus disease-2019 (COVID-19) pandemic has affected millions worldwide. The various complications of COVID-19 have been discussed in the recent studies. We would like to discuss about one such cardiovascular complication, ST elevation myocardial infarction (STEMI) in COVID-19, and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Journal of Clinical and Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.jcpconline.org/article.asp?issn=2250-3528;year=2021;volume=10;issue=2;spage=58;epage=62;aulast=Jena |
| _version_ | 1818354962261868544 |
|---|---|
| author | Kamal Kant Jena G Manohar C Elamaran A Rudrappa |
| author_facet | Kamal Kant Jena G Manohar C Elamaran A Rudrappa |
| author_sort | Kamal Kant Jena |
| collection | DOAJ |
| description | Background: Coronavirus disease-2019 (COVID-19) pandemic has affected millions worldwide. The various complications of COVID-19 have been discussed in the recent studies. We would like to discuss about one such cardiovascular complication, ST elevation myocardial infarction (STEMI) in COVID-19, and its characteristics in this article. Methodology: An observational study was done from April 1, 2020, to July 15, 2020, selecting all STEMI patients admitted to a tertiary care center in Chennai and treated with tenecteplase were grouped in to COVID-19 positive and negative. Their presenting features and complications and outcome were studied. Results: A total of 300 patients were admitted with STEMI during the study period, of which 11.66% were COVID-19 positive. Atherosclerotic cardiovascular risk factors were much lower in COVID-19-positive STEMI patients when compared to non-COVID STEMI patients. Mean oxygen saturation at time of presentation in COVID-19 positive and negative patients was 85.1% and 97.5%, respectively (P < 0.001). COVID-19 group had significantly higher noncardiac complications than non-COVID patients (P < 0.001). The average duration of hospital stay in COVID-19 STEMI was 13.6 days, whereas in non-COVID group was 6.8 days (P < 0.001). Higher mortality was found in the COVID-19 positive group (14.28%) when compared to non-COVID STEMI (7.9%; P < 0.001). Conclusion: COVID-19 itself is a systemic inflammatory disease, which could increase the risk of coronary plaque rupture. Thrombosis has also been described as a mechanism underlying certain cases causing presentation of STEMI, because of endothelial dysfunction and hypercoagulable state. |
| first_indexed | 2024-12-13T19:33:45Z |
| format | Article |
| id | doaj.art-e962804ea4e44b73a856ca22e373219c |
| institution | Directory Open Access Journal |
| issn | 2250-3528 |
| language | English |
| last_indexed | 2024-12-13T19:33:45Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Clinical and Preventive Cardiology |
| spelling | doaj.art-e962804ea4e44b73a856ca22e373219c2022-12-21T23:33:52ZengWolters Kluwer Medknow PublicationsJournal of Clinical and Preventive Cardiology2250-35282021-01-01102586210.4103/jcpc.jcpc_64_20Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative studyKamal Kant JenaG ManoharC ElamaranA RudrappaBackground: Coronavirus disease-2019 (COVID-19) pandemic has affected millions worldwide. The various complications of COVID-19 have been discussed in the recent studies. We would like to discuss about one such cardiovascular complication, ST elevation myocardial infarction (STEMI) in COVID-19, and its characteristics in this article. Methodology: An observational study was done from April 1, 2020, to July 15, 2020, selecting all STEMI patients admitted to a tertiary care center in Chennai and treated with tenecteplase were grouped in to COVID-19 positive and negative. Their presenting features and complications and outcome were studied. Results: A total of 300 patients were admitted with STEMI during the study period, of which 11.66% were COVID-19 positive. Atherosclerotic cardiovascular risk factors were much lower in COVID-19-positive STEMI patients when compared to non-COVID STEMI patients. Mean oxygen saturation at time of presentation in COVID-19 positive and negative patients was 85.1% and 97.5%, respectively (P < 0.001). COVID-19 group had significantly higher noncardiac complications than non-COVID patients (P < 0.001). The average duration of hospital stay in COVID-19 STEMI was 13.6 days, whereas in non-COVID group was 6.8 days (P < 0.001). Higher mortality was found in the COVID-19 positive group (14.28%) when compared to non-COVID STEMI (7.9%; P < 0.001). Conclusion: COVID-19 itself is a systemic inflammatory disease, which could increase the risk of coronary plaque rupture. Thrombosis has also been described as a mechanism underlying certain cases causing presentation of STEMI, because of endothelial dysfunction and hypercoagulable state.http://www.jcpconline.org/article.asp?issn=2250-3528;year=2021;volume=10;issue=2;spage=58;epage=62;aulast=Jenaacute myocardial infarctioncoronavirus disease-2019fibrinolysishypercoagulabilityrisk factors |
| spellingShingle | Kamal Kant Jena G Manohar C Elamaran A Rudrappa Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative study Journal of Clinical and Preventive Cardiology acute myocardial infarction coronavirus disease-2019 fibrinolysis hypercoagulability risk factors |
| title | Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative study |
| title_full | Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative study |
| title_fullStr | Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative study |
| title_full_unstemmed | Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative study |
| title_short | Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative study |
| title_sort | clinical profile of st elevation myocardial infarction thrombolysed with tenecteplase in coronavirus disease 2019 pandemic a comparative study |
| topic | acute myocardial infarction coronavirus disease-2019 fibrinolysis hypercoagulability risk factors |
| url | http://www.jcpconline.org/article.asp?issn=2250-3528;year=2021;volume=10;issue=2;spage=58;epage=62;aulast=Jena |
| work_keys_str_mv | AT kamalkantjena clinicalprofileofstelevationmyocardialinfarctionthrombolysedwithtenecteplaseincoronavirusdisease2019pandemicacomparativestudy AT gmanohar clinicalprofileofstelevationmyocardialinfarctionthrombolysedwithtenecteplaseincoronavirusdisease2019pandemicacomparativestudy AT celamaran clinicalprofileofstelevationmyocardialinfarctionthrombolysedwithtenecteplaseincoronavirusdisease2019pandemicacomparativestudy AT arudrappa clinicalprofileofstelevationmyocardialinfarctionthrombolysedwithtenecteplaseincoronavirusdisease2019pandemicacomparativestudy |